Candidate Genes for the Progression of Malignant Gliomas Identified by Microarray Analysis

Overview

Journal Neurosurg Rev

Specialty Neurosurgery

Date 2007 Oct 6

PMID 17917751

Citations 11

Authors

Oliver Bozinov

Sylvia Kohler

Birgit Samans

Ludwig Benes

Dorothea Miller

Markus Ritter

Ulrich Sure

Helmut Bertalanffy

Affiliations

Soon will be listed here.

Abstract

Malignant astrocytomas of World Health Organization (WHO) grade III or IV have a reduced median survival time, and possible pathways have been described for the progression of anaplastic astrocytomas and glioblastomas, but the molecular basis of malignant astrocytoma progression is still poorly understood. Microarray analysis provides the chance to accelerate studies by comparison of the expression of thousands of genes in these tumours and consequently identify targeting genes. We compared the transcriptional profile of 4,608 genes in tumours of 15 patients including 6 anaplastic astrocytomas (WHO grade III) and 9 glioblastomas (WHO grade IV) using microarray analysis. The microarray data were corroborated by real-time reverse transcription-polymerase chain reaction analysis of two selected genes. We identified 166 gene alterations with a fold change of 2 and higher whose mRNA levels differed (absolute value of the t statistic of 1.96) between the two malignant glioma groups. Further analyses confirmed same transcription directions for Olig2 and IL-13Ralpha2 in anaplastic astrocytomas as compared to glioblastomas. Microarray analyses with a close binary question reveal numerous interesting candidate genes, which need further histochemical testing after selection for confirmation. IL-13Ralpha2 and Olig2 have been identified and confirmed to be interesting candidate genes whose differential expression likely plays a role in malignant progression of astrocytomas.

Citing Articles

A Novel Multi-Omics Analysis Model for Diagnosis and Survival Prediction of Lower-Grade Glioma Patients.

Wu W, Wang Y, Xiang J, Li X, Wahafu A, Yu X Front Oncol. 2022; 12:729002.

PMID: 35646656 PMC: 9133344. DOI: 10.3389/fonc.2022.729002.

A double helical motif in OCIAD2 is essential for its localization, interactions and STAT3 activation.

Sinha S, Bheemsetty V, Inamdar M Sci Rep. 2018; 8(1):7362.

PMID: 29743632 PMC: 5943604. DOI: 10.1038/s41598-018-25667-3.

Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data.

Vastrad B, Vastrad C, Godavarthi A, Chandrashekar R Med Oncol. 2017; 34(11):182.

PMID: 28952134 DOI: 10.1007/s12032-017-1043-x.

OCIAD2 suppressed tumor growth and invasion via AKT pathway in Hepatocelluar carcinoma.

Wu D, Yang X, Peng H, Guo D, Zhao W, Zhao C Carcinogenesis. 2017; 38(9):910-919.

PMID: 28911005 PMC: 6248579. DOI: 10.1093/carcin/bgx073.

A 16-gene signature distinguishes anaplastic astrocytoma from glioblastoma.

Rao S, Srinivasan S, Patric I, Hegde A, Chandramouli B, Arimappamagan A PLoS One. 2014; 9(1):e85200.

PMID: 24475040 PMC: 3901657. DOI: 10.1371/journal.pone.0085200.

References

Kawakami K, Kioi M, Liu Q, Kawakami M, Puri R . Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy. J Immunother. 2005; 28(3):193-202. DOI: 10.1097/01.cji.0000161393.04207.e1. View

Kawakami M, Kawakami K, Takahashi S, Abe M, Puri R . Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors. Cancer. 2004; 101(5):1036-42. DOI: 10.1002/cncr.20470. View

Shai R, Shi T, Kremen T, Horvath S, Liau L, Cloughesy T . Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 2003; 22(31):4918-23. DOI: 10.1038/sj.onc.1206753. View

Pomeroy S, Tamayo P, Gaasenbeek M, Sturla L, Angelo M, McLaughlin M . Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002; 415(6870):436-42. DOI: 10.1038/415436a. View

Wennerberg K, Rossman K, Der C . The Ras superfamily at a glance. J Cell Sci. 2005; 118(Pt 5):843-6. DOI: 10.1242/jcs.01660. View

Fuller G, Hess K, Rhee C, Yung W, Sawaya R, Bruner J . Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol. 2002; 12(1):108-16. PMC: 8096049. DOI: 10.1111/j.1750-3639.2002.tb00427.x. View

Bouvier C, Bartoli C, Aguirre-Cruz L, Virard I, Colin C, Fernandez C . Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. J Neurosurg. 2003; 99(2):344-50. DOI: 10.3171/jns.2003.99.2.0344. View

Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black P, Muzikansky A . The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004; 22(10):1926-33. DOI: 10.1200/JCO.2004.07.193. View

Joshi B, Plautz G, Puri R . Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 2000; 60(5):1168-72. View

10.

Kawakami K, Kawakami M, Snoy P, Husain S, Puri R . In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med. 2001; 194(12):1743-54. PMC: 2193574. DOI: 10.1084/jem.194.12.1743. View

11.

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

12.

Mischel P, Shai R, Shi T, Horvath S, Lu K, Choe G . Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 2003; 22(15):2361-73. DOI: 10.1038/sj.onc.1206344. View

13.

Wang J, Escalon E, Carroll A, de Jong P, Kirsch I, Aplan P . The t(14;21)(q11.2;q22) chromosomal translocation associated with T-cell acute lymphoblastic leukemia activates the BHLHB1 gene. Proc Natl Acad Sci U S A. 2000; 97(7):3497-502. PMC: 16268. DOI: 10.1073/pnas.97.7.3497. View

14.

Freije W, Castro-Vargas F, Fang Z, Horvath S, Cloughesy T, Liau L . Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004; 64(18):6503-10. DOI: 10.1158/0008-5472.CAN-04-0452. View

15.

Fukuda S, Kondo T, Takebayashi H, Taga T . Negative regulatory effect of an oligodendrocytic bHLH factor OLIG2 on the astrocytic differentiation pathway. Cell Death Differ. 2003; 11(2):196-202. DOI: 10.1038/sj.cdd.4401332. View

16.

Sanson M, Thillet J, Hoang-Xuan K . Molecular changes in gliomas. Curr Opin Oncol. 2005; 16(6):607-13. DOI: 10.1097/01.cco.0000142485.81849.cc. View

17.

Reifenberger G, Collins V . Pathology and molecular genetics of astrocytic gliomas. J Mol Med (Berl). 2004; 82(10):656-70. DOI: 10.1007/s00109-004-0564-x. View

18.

Lu Q, Park J, Noll E, Chan J, Alberta J, Yuk D . Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U S A. 2001; 98(19):10851-6. PMC: 58563. DOI: 10.1073/pnas.181340798. View

19.

Schramm A, Schulte J, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B . Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene. 2005; 24(53):7902-12. DOI: 10.1038/sj.onc.1208936. View

20.

Rich J, Reardon D, Peery T, Dowell J, Quinn J, Penne K . Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2003; 22(1):133-42. DOI: 10.1200/JCO.2004.08.110. View